Targeting of interleukin-17 in the treatment of psoriasis
Ann Sophie Lønnberg, Claus Zachariae, Lone SkovDepartment of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, DenmarkAbstract: “Psoriasis” is a chronic immune-mediated inflammatory disorder with epidermal hyperplasia. There is some evidence t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-09-01
|
| Series: | Clinical, Cosmetic and Investigational Dermatology |
| Online Access: | http://www.dovepress.com/targeting-of-interleukin-17-in-the-treatment-of-psoriasis-peer-reviewed-article-CCID |
| _version_ | 1819119276014960640 |
|---|---|
| author | Lønnberg AS Zachariae C Skov L |
| author_facet | Lønnberg AS Zachariae C Skov L |
| author_sort | Lønnberg AS |
| collection | DOAJ |
| description | Ann Sophie Lønnberg, Claus Zachariae, Lone SkovDepartment of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, DenmarkAbstract: “Psoriasis” is a chronic immune-mediated inflammatory disorder with epidermal hyperplasia. There is some evidence that the cytokine interleukin-17A (often known as IL-17), which is mainly produced by Th17 cells, has a role in the pathogenesis of psoriasis. “IL-17” is a pro-inflammatory cytokine mainly important in the host's defense against extracellular bacteria and fungi. The three new therapies with biologic drugs – brodalumab, secukinumab, and ixekizumab – all target the IL-17 signaling pathway. Secukinumab and ixekizumab neutralize IL-17A, while brodalumab blocks its receptor. Results from clinical trials have shown marked improvements in disease severity in patients with moderate-to-severe plaque psoriasis, using any of these three drugs. The biologic agents were generally well tolerated, but the duration of the trials was relatively short. In this review, we focus on the role of the IL-17 cytokine family in the pathogenesis of psoriasis; the efficacy, safety, and tolerability of brodalumab, secukinumab, and ixekizumab in clinical trials; and possible differences between targeting of the IL-17A receptor and targeting of the IL-17A ligand.Keywords: anti-IL-17 agents, IL-17, brodalumab, secukinumab, ixekizumab, psoriasis |
| first_indexed | 2024-12-22T06:02:11Z |
| format | Article |
| id | doaj.art-7d6e91357869499a83c635f5d88bcfe1 |
| institution | Directory Open Access Journal |
| issn | 1178-7015 |
| language | English |
| last_indexed | 2024-12-22T06:02:11Z |
| publishDate | 2014-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical, Cosmetic and Investigational Dermatology |
| spelling | doaj.art-7d6e91357869499a83c635f5d88bcfe12022-12-21T18:36:32ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152014-09-012014default25125918345Targeting of interleukin-17 in the treatment of psoriasisLønnberg ASZachariae CSkov LAnn Sophie Lønnberg, Claus Zachariae, Lone SkovDepartment of Dermato-Allergology, Gentofte Hospital, University of Copenhagen, Hellerup, DenmarkAbstract: “Psoriasis” is a chronic immune-mediated inflammatory disorder with epidermal hyperplasia. There is some evidence that the cytokine interleukin-17A (often known as IL-17), which is mainly produced by Th17 cells, has a role in the pathogenesis of psoriasis. “IL-17” is a pro-inflammatory cytokine mainly important in the host's defense against extracellular bacteria and fungi. The three new therapies with biologic drugs – brodalumab, secukinumab, and ixekizumab – all target the IL-17 signaling pathway. Secukinumab and ixekizumab neutralize IL-17A, while brodalumab blocks its receptor. Results from clinical trials have shown marked improvements in disease severity in patients with moderate-to-severe plaque psoriasis, using any of these three drugs. The biologic agents were generally well tolerated, but the duration of the trials was relatively short. In this review, we focus on the role of the IL-17 cytokine family in the pathogenesis of psoriasis; the efficacy, safety, and tolerability of brodalumab, secukinumab, and ixekizumab in clinical trials; and possible differences between targeting of the IL-17A receptor and targeting of the IL-17A ligand.Keywords: anti-IL-17 agents, IL-17, brodalumab, secukinumab, ixekizumab, psoriasishttp://www.dovepress.com/targeting-of-interleukin-17-in-the-treatment-of-psoriasis-peer-reviewed-article-CCID |
| spellingShingle | Lønnberg AS Zachariae C Skov L Targeting of interleukin-17 in the treatment of psoriasis Clinical, Cosmetic and Investigational Dermatology |
| title | Targeting of interleukin-17 in the treatment of psoriasis |
| title_full | Targeting of interleukin-17 in the treatment of psoriasis |
| title_fullStr | Targeting of interleukin-17 in the treatment of psoriasis |
| title_full_unstemmed | Targeting of interleukin-17 in the treatment of psoriasis |
| title_short | Targeting of interleukin-17 in the treatment of psoriasis |
| title_sort | targeting of interleukin 17 in the treatment of psoriasis |
| url | http://www.dovepress.com/targeting-of-interleukin-17-in-the-treatment-of-psoriasis-peer-reviewed-article-CCID |
| work_keys_str_mv | AT loslashnnbergas targetingofinterleukin17inthetreatmentofpsoriasis AT zachariaec targetingofinterleukin17inthetreatmentofpsoriasis AT skovl targetingofinterleukin17inthetreatmentofpsoriasis |